Vectura Group PLC (LON:VEC) hit a new 52-week low during trading on Wednesday after Peel Hunt lowered their price target on the stock from GBX 160 to GBX 120. Peel Hunt currently has a hold rating on the stock. Vectura Group traded as low as GBX 70.50 ($0.97) and last traded at GBX 76 ($1.05), with a volume of 11630000 shares traded. The stock had previously closed at GBX 78.10 ($1.08).

VEC has been the subject of a number of other research reports. Shore Capital reiterated a “buy” rating on shares of Vectura Group in a research note on Thursday, November 9th. Numis Securities reiterated a “buy” rating and issued a GBX 170 ($2.35) target price on shares of Vectura Group in a research note on Thursday, January 4th. Royal Bank of Canada upgraded Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) target price for the company in a research note on Thursday, December 14th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Vectura Group in a research note on Monday, January 15th. Finally, Panmure Gordon reiterated a “buy” rating and issued a GBX 150 ($2.07) target price on shares of Vectura Group in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Vectura Group currently has a consensus rating of “Buy” and an average price target of GBX 169.56 ($2.34).

COPYRIGHT VIOLATION WARNING: “Vectura Group (VEC) Reaches New 52-Week Low Following Analyst Downgrade” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/15/vectura-group-vec-reaches-new-52-week-low-following-analyst-downgrade.html.

Vectura Group Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.